Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Stephane De Botton, Thomas Cluzeau, MDPhD, Carlos Enrique Vigil, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Jane L. Liesveld, MD, Pierre Fenaux, MD PhD, Thorsten Braun, MD PhD, Anne Banos, MD, Michael R. Savona, MD, Don Park, MD, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Eytan M. Stein, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134600

Published: 2020

Journal Articles

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Eytan M. Stein, MD, Stephane De Botton, Thomas Cluzeau, MDPhD, Arnaud Pigneux, MD PhD, Jane L. Liesveld, MD, Rachel J. Cook, MD, Philippe Rousselot, MDPhD, David A Rizzieri, MD, Thorsten Braun, MD PhD, Dale L. Bixby, MD, Gail J. Roboz, MD, Delphine Lebon, MD, Mael Heiblig, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Qing Kang-Fortner, PhD, David A. Roth, MD, Pierre Peterlin, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-134602

Published: 2020

Journal Articles

Selection of RARA-Positive Newly Diagnosed Unfit AML Patients with Elevated RARA Gene Expression Enriches for Features Associated with Primary Resistance to Venetoclax and Clinical Response to SY-1425, a Potent and Selective RARα Agonist, Plus Azacitidine

Christopher Fiore, PhD, Michael J. Kelly, MD MPH, MS, Angela Volkert, Li Zhou, PhD, Kate Madigan, MD, Matthew Eaton, PhD, Graeme Hodgson, PhD, David A. Roth, MD, Qing Kang-Fortner, PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-137323

Published: 2020

Journal Articles

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

Andres Forero-Torres, MD, Rod Ramchandren, MD, Abdulraheem Yacoub, MD, Michael S. Wertheim, MD, William J. Edenfield, MD, Paolo Caimi, MD, Martin Gutierrez, MD, Luke Akard, MD, Carolina Escobar, MD, Justin Call, MD, Daniel Persky, MD, Swami P. Iyer, MD, Douglas J. DeMarini, PhD, Li Zhou, PhD, Swamy Yeleswaram, PhD, Tycel J. Phillips, MD

Blood (2017) 130 (Supplement 1): 410.

https://doi.org/10.1182/blood.V130.Suppl_1.410.410

Published: 2017

Journal Articles

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Tycel Phillips, MD, Rod Ramchandren, MD, Michael S Wertheim, MD, Martin E Gutierrez, MD, William J Edenfield, MD, Fitzroy Dawkins, MD, Doug J DeMarini, Li Zhou, PhD, Swamy Yeleswaram, PhD, Robert C Newton, PhD, Xuejun Chen, PhD, Andres Forero-Torres, MD

Blood (2016) 128 (22): 4195.

https://doi.org/10.1182/blood.V128.22.4195.4195

Published: 2016

Journal Articles

Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia

Thomas B. Alexander, MD MPH, Zhaohui Gu, PhD, John K Choi, MD, Mignon L. Loh, MD, John Horan, MD MPH, Barbara Buldini, MD, Giuseppe Basso, Sarah Elitzur, MD, C. Michel Zwaan, MD PhD, Valerie de Haas, MD PhD, Allen Eng Juh Yeoh, MD, Dirk Reinhardt, MD PhD, Daisuke Tomizawa, MD, PhD, Tim Lammens, Barbara De Moerloose, MD, Li Zhou, PhD, Hiroki Hori, MD PhD, Anthony V. Moorman, PhD, Andrew S. Moore, MBBS FRACP PhD, Ondrej Hrusak, MD PhD, Soheil Meshinchi, MD PhD, Etan Orgel, MD MS, Meenakshi Devidas, PhD, Stephen P. Hunger, MD, Jamie M Guidry Auvil, Malcolm A. Smith, MD PhD, Tanja M. Davidsen, PhD, Leandro C. Hermida, Patee Gesuwan, Marco A. Marra, PhD, Yussanne Ma, PhD, Andrew J. Mungall, Richard Moore, PhD, Daniela S. Gerhard, PhD, Xueyuan Cao, Lei Shi, PhD, Stanley Pounds, PhD, Hiroto Inaba, MD PhD, Charles Mullighan, MBBS, MSc, MD

Blood (2016) 128 (22): 454.

https://doi.org/10.1182/blood.V128.22.454.454

Published: 2016

Journal Articles

Age-Adjusted Telomere Length May Predict Treatment-Related Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation

Pasquale M Barbaro, MBBS FRACP FRCPA, Peter J. Shaw, MBBS, FRACP, MA, MRCP, Melissa Gabriel, MBBS, FRACP, Steven Keogh, MBBS (Hons), FRACP, Li Zhou, PhD, Daniel Catchpole, PhDFFSc(RCPA), Loretta Lau, MBBS, MMed, PhD FRACP, Rebecca Dagg, BSc (Hons), Hilda A Pickett, BSc (Hons) PhD, Roger R Reddel, BSc (MD MBBS PhDFRACP FAA

Blood (2015) 126 (23): 5445.

https://doi.org/10.1182/blood.V126.23.5445.5445

Published: 2015

Journal Articles

Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML

Blood (2012) 120 (21): 1875.

https://doi.org/10.1182/blood.V120.21.1875.1875

Published: 2012

Journal Articles

Mir-21 Mediates Hematopoietic Suppression in MDS by Activating TGF-b Signaling,

Tushar D. Bhagat, M.S., Li Zhou, PhD, Lubomir Sokol, MD, PhD, Ioannis Mantzaris, MD, Krishna Gundabolu, MD, Shanisha A. K. Gordon, Yiting Yu, PhD, Sangeeta Nischal, Ph.D., Rahul Polineni, MD, Carolina Schinke, M.D., Grigorios Chrysofakis, M.D., Amittha Wickrema, PhD, Andrea Pellagatti, Jacqueline Boultwood, PhD, Ulrich G Steidl, MD, PhD, Gang Liu, MD., Ph.D., Alan F List, MD, Markus Bitzer, M.D., Amit Verma, MD

Blood (2011) 118 (21): 3813.

https://doi.org/10.1182/blood.V118.21.3813.3813

Published: 2011

Journal Articles

Dysregulation of TGF-Beta Stimulated Smad Signaling Is Seen in Myelodysplasia and Points to the Potential Therapeutic Efficacy of TGF-Beta Receptor I Kinase Inhibition in Low Grade Disease.

Blood (2009) 114 (22): 737.

https://doi.org/10.1182/blood.V114.22.737.737

Published: 2009

NARROW

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia

Selection of RARA-Positive Newly Diagnosed Unfit AML Patients with Elevated RARA Gene Expression Enriches for Features Associated with Primary Resistance to Venetoclax and Clinical Response to SY-1425, a Potent and Selective RARα Agonist, Plus Azacitidine

Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients with Relapsed or Refractory B-Cell Malignancies (CITADEL-101)

An Ongoing Open-Label Phase 1/2 Study of INCB050465, a Selective PI3Kδ Inhibitor, in Patients with Previously Treated B-Cell Malignancies

Genomic Landscape of Pediatric Mixed Phenotype Acute Leukemia

Age-Adjusted Telomere Length May Predict Treatment-Related Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation

Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML

Mir-21 Mediates Hematopoietic Suppression in MDS by Activating TGF-b Signaling,

Dysregulation of TGF-Beta Stimulated Smad Signaling Is Seen in Myelodysplasia and Points to the Potential Therapeutic Efficacy of TGF-Beta Receptor I Kinase Inhibition in Low Grade Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only